Table 1 |
||||||||||
|
Pooling design for ER-positive versus ER-negative cryogenic whole tumor sections |
||||||||||
|
Experimental variable designation |
Pools |
Tumor number |
RNA quality |
Tumor status |
Lymph node status |
Grade |
ER status |
PR status |
Her2/neu status |
Age of patient (years) |
|
|
||||||||||
|
ER positive |
T378 |
ok |
2 |
0 |
2 |
12 |
4 |
0 |
75 |
|
|
ER+1 |
|
|||||||||
|
T392 |
ok |
2 |
0 |
2 |
12 |
2 |
2a |
61 |
||
|
|
||||||||||
|
T460 |
ok |
2 |
0 |
2 |
4 |
8 |
3 |
79 |
||
|
ER+2 |
|
|||||||||
|
T464 |
ok |
2 |
0 |
2 |
12 |
8 |
0 |
50 |
||
|
|
||||||||||
|
T288 |
ok |
2 |
0 |
2 |
12 |
4 |
1 |
76 |
||
|
ER+3 |
|
|||||||||
|
T711 |
ok |
4 |
2 |
3 |
8 |
6 |
0 |
65 |
||
|
|
||||||||||
|
T712 |
ok |
2 |
1 |
2 |
9 |
4 |
0 |
58 |
||
|
ER+4 |
|
|||||||||
|
T425 |
ok |
2 |
1 |
2 |
12 |
0 |
0 |
78 |
||
|
|
||||||||||
|
ER negative |
T433 |
ok |
2 |
0 |
2 |
0 |
0 |
1 |
42 |
|
|
ER-1 |
|
|||||||||
|
T443 |
ok |
2 |
1 |
2 |
0 |
12 |
0 |
46 |
||
|
|
||||||||||
|
T469 |
ok |
1 |
0 |
2–3 |
0 |
0 |
3 |
50 |
||
|
ER-2 |
|
|||||||||
|
T470 |
ok |
2 |
1 |
2 |
0 |
0 |
0 |
39 |
||
|
|
||||||||||
|
T531 |
ok |
2 |
0 |
2 |
0 |
0 |
0 |
58 |
||
|
ER-3 |
|
|||||||||
|
T558 |
ok |
2 |
0 |
2–3 |
0 |
0 |
0 |
62 |
||
|
|
||||||||||
|
T623 |
ok |
1 |
x |
2–3 |
0 |
0 |
1 |
42 |
||
|
ER-4 |
|
|||||||||
|
T640 |
ok |
2 |
0 |
3 |
0 |
0 |
3 |
62 |
||
|
|
||||||||||
|
Individual tumors are designated by their tumor bank T registration numbers. Experimental, clinical, and histopathological parameters are listed. Eight ER-positive and eight ER-negative tumors are grouped into four pools of two tumors each, as indicated. Clinical data comprise the following: tumor status ranging from pT1 (tumor 2 cm or smaller in greatest dimension) to pT3 (tumor >5 cm); lymph node status from pN0 (no regional lymph node metastasis) to pN3 (metastasis to ipsilateral internal mammary lymph nodes [s]) and pNx (regional lymph node cannot be assessed); tumor grade from 2 (moderately differentiated) to 3 (poorly differentiated); histopathologic data for ER and PR (0 = undetectable; 1 to 3 = weakly positive; 4 to 7 = moderately positive; 8–12 = highly positive); and Her2/neu-status (0 = negative, positive +1 to +3). Ages for each patient are given in years. aNo gene amplification detected. x, pNx regional lymphnodes cannot be assessed. ER, estrogen receptor; HER, human epidermal growth factor receptor; PR, progesterone receptor. |
||||||||||
|
Neubauer et al. Breast Cancer Research 2008 10:R85 doi:10.1186/bcr2155 |
||||||||||
